Ocrelizumab: a B-cell depleting therapy for multiple sclerosis

References

• Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231–266.
   PubMedGoogle Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903–912.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–218.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452–461.
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009;65(6):639–649.
   PubMed Web of Science ®Google Scholar
• Hauser SL. The Charcot Lecture |beating MS: a story of B cells, with twists and turns. Mult Scler. 2015;21(1):8–21.
   PubMed Web of Science ®Google Scholar
• Harp CT, Lovett-Racke AE, Racke MK, et al. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol. 2008;128(3):382–391.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164–174.
   PubMed Web of Science ®Google Scholar
• Bartok B, Silverman GJ. Development of anti-CD20 therapy for multiple sclerosis. Exp Cell Res. 2011;317(9):1312–1318.
   PubMed Web of Science ®Google Scholar
• Zouali M, Tsay G. Developing connections amongst B lymphocytes and deregulated pathways in autoimmunity. Mol Med. 2016;22.
   PubMed Web of Science ®Google Scholar
• Ireland SJ, Guzman AA, Frohman EM, et al. B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J Neuroimmunol. 2016;291:46–53.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Bornsen L, Ratzer R, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013;8(3):e57820.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129(Pt 1):200–211.
   PubMed Web of Science ®Google Scholar
• Serafini B, Severa M, Columba-Cabezas S, et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010;69(7):677–693.
   PubMed Web of Science ®Google Scholar
• Parker Harp CR, Archambault AS, Sim J, et al. B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis. J Immunol. 2015;194(11):5077–5084.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089–1104.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Cerza N, Hagemeier J, et al. Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e190.
   PubMed Web of Science ®Google Scholar
• Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613–623.
   PubMed Web of Science ®Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715.
   PubMed Web of Science ®Google Scholar
• Hartung DM, Bourdette DN, Ahmed SM, et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84(21):2185–2192.
   PubMed Web of Science ®Google Scholar
• Moccia M, Palladino R, Lanzillo R, et al. Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurol Scand. 2017;135(5):522–528.
   PubMed Web of Science ®Google Scholar
• ICER. Multiple sclerosis: evidence Report – ICER [online].[ cited 2017 Feb 15]; Available from: https://icer-review.org/material/ms-evidence-report/
   Google Scholar
• Gold R, Toumi M, Meesen B, et al. The payer’s perspective: what is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Mult Scler. 2016;22(2 Suppl):60–70.
   PubMed Web of Science ®Google Scholar
• Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - a systematic review. PLoS One. 2016;11(7):e0159129.
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28(5):363–379.
   PubMed Web of Science ®Google Scholar
• Kolasa K. How much is the cost of multiple sclerosis–systematic literature review. Przegl Epidemiol. 2013;67(1):75-79, 157-160.
   Google Scholar
• Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986–995e981.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. ASH Education Program Book. 2007 Jan 1;2007(1):226–232.
   Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus. 2004;13(5):381–390.
   PubMed Web of Science ®Google Scholar
• Du J, Yang H, Guo Y, et al. Structure of the fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46(11–12):2419–2423.
   PubMed Web of Science ®Google Scholar
• Fischer SK, Yang J, Anand B, et al. The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: case studies. MAbs. 2012;4(5):623–631.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010;21(9):1870–1876.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140–174.
   PubMedGoogle Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676–690.
   PubMed Web of Science ®Google Scholar
• Melis JP, Strumane K, Ruuls SR, et al. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol. 2015;67(2 Pt A):117–130.
   PubMed Web of Science ®Google Scholar
• Engelberts PJ, Voorhorst M, Schuurman J, et al. Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B Cells. J Immunol. 2016;197(12):4829–4837.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754–758.
   PubMed Web of Science ®Google Scholar
• Pross HF, Maroun JA. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods. 1984;68(1–2):235–249.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–1685.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Huffstutter JE, Taylor J, Schechtman J, et al. Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the phase III FEATURE trial. Int J Clin Rheumtol. 2011;6(6):689–696.
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Kappos L, Calabresi P, O’Connor P, et al. Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. In 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2012 Oct 10 (p. 362).
   Google Scholar
• Traboulsee A, Giovannoni G, Bar-Or A, et al. NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II Phase III Studies. Mult Scler. 2017;23(1_suppl):2–90.
   Web of Science ®Google Scholar
• Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152–158. .
   PubMed Web of Science ®Google Scholar
• Uher T, Havrdova E, Sobisek L, et al. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? Mult Scler. 2017;23(2):242–252.
   PubMed Web of Science ®Google Scholar
• Cree BA, Gourraud PA, Gourraud PA, Oksenberg JR, et al. University of California SFMSET; Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016;80(4):499–510.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14–24.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460–471.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Montalban X, Arnold D, et al. Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Mult Scler. 2017;29(1):2–90.
   Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379.
   PubMed Web of Science ®Google Scholar
• Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):360–370.
   PubMed Web of Science ®Google Scholar
• Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):350–359.
   PubMed Web of Science ®Google Scholar
• Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012;71(8):1289–1296.
   PubMed Web of Science ®Google Scholar
• Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9(2):e87379.
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Stys PK, Minagar A, et al. Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci. 2009;282(1–2):12–20.
   PubMed Web of Science ®Google Scholar
• Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(Pt 9):2755–2771.
   PubMed Web of Science ®Google Scholar
• Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135(Pt 10):2925–2937.
   PubMed Web of Science ®Google Scholar
• Zurawski J, Lassmann H, Bakshi R. Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: a review. JAMA Neurol. 2017;74(1):100–109.
   PubMed Web of Science ®Google Scholar
• Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015;85(1):18–28.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Ramasamy DP, Vaneckova M, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler. 2016;1352458516678083.
   Google Scholar
• Borie D, Kremer JM. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015;45(2):163–166.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573–581.
   PubMed Web of Science ®Google Scholar
• Ben Abdelwahed R, Donnou S, Ouakrim H, et al. Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci. 2013;54(5):3657–3665.
   PubMed Web of Science ®Google Scholar
• TG Therapeutics I. Phase 2 study of ublituximab in patients with relapsing forms of multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-2017 Feb 09. NLM Identifier: NCT02738775). Available from: https://clinicaltrials.gov/ct2/show/record/NCT02738775
   Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33.
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282(20):15073–15080.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Ofatumumab subcutaneous administration in subjects with relapsing-remitting multiple sclerosis (MIRROR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-2017 Feb 09. NLM Identifier: NCT01457924). Available from: https://clinicaltrials.gov/ct2/show/record/NCT01457924
   Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839.
   PubMed Web of Science ®Google Scholar
• MedImmune L. Safety and tolerability study of MEDI-551, a B-cell depleting agent, to treat relapsing forms of multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-2017 Feb 09. NLM Identifier: NCT01585766). Available from: https://clinicaltrials.gov/ct2/show/record/NCT01585766
   Google Scholar
• Novartis. A study to assess the effect of a single infusion of VAY736 on disease activity in patients with relapsing-remitting multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-2017 Feb 09. NLM Identifier: NCT02038049). Available from: https://clinicaltrials.gov/ct2/show/NCT02038049
   Google Scholar
• Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213–222.
   PubMed Web of Science ®Google Scholar
• MedImmune L. A double-masked, placebo-controlled study with open label period to evaluate MEDI-551 in neuromyelitis optica and neuromyelitis optica spectrum disorders. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000-2017 Feb 09. NLM Identifier: NCT02200770). Available from: https://clinicaltrials.gov/ct2/show/NCT02200770
   Google Scholar
• Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195–200.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008;131(Pt 6):1455–1463.
   PubMed Web of Science ®Google Scholar
• Kappos L, Hartung HP, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13(4):353–363.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Jakimovski D, Ahmed R, et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016;16(9):1151–1162.
   PubMed Web of Science ®Google Scholar
• Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–3342.
   PubMed Web of Science ®Google Scholar
• Roche. U.S. FDA grants breakthrough therapy designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis. [ cited 2017 Feb 12; Available from: http://www.roche.com/investors/updates/inv-update-2016-02-17.htm
   Google Scholar